Work

Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids

Year: 2022

Type: article

Abstract: (Cell Reports 39, 110733; April 26, 2022) In the original published version of this paper, a declaration of interests was accidently omitted: “B.N.F. is a member of the scientific advisory board and has stock in Cirius Therapeutics, which is developing MPC inhibitors for clinical use.” This has been corrected online. The authors apologize for this error. Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acidsMartino et al.Cell ReportsApril 26, 2022In BriefMartino et al. find that alanine transaminase 2 (ALT2), which is encoded by Gpt2, is increased in liver of mice and people with obesity by activating transcription factor 4. Suppression of Gpt2 expression in obese, but not lean mice, lowers blood glucose by suppressing alanine-mediated gluconeogenesis. Full-Text PDF Open Access

Source: Cell Reports

DOI: 10.1016/j.celrep.2022.111633